To study the effect of monocrotaline on the pulmonary alveolar-capillary membrane permeability, cardiac catheterization, extravascular lung water content and absorption of 14C-compoundsfrom the rat lungs in combination with morphological observations were studied in the early stage of monocrotaline intoxication.
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To study the effect of monocrotaline on the pulmonary alveolar-capillary membrane permeability, cardiac catheterization, extravascular lung water content and absorption of 14C-compoundsfrom the rat lungs in combination with morphological observations were studied in the early stage of monocrotaline intoxication.
Purified monocrotaline or its pyrrole was administered to rats with various doses. Single dose of 50mg/kg of monocrotaline was enough to induce pulmonary hypertension 4 weeks later, but neither immediate nor direct pressor effect was observed by monocrotaline or active pyrrole. Only 3 to 5mg /kg of pyrrole was enough to produce alveolar flooding with increased extravascular lung water content and accelerated absorption of 14C-mannitol and 14C-inulin from lungs 24 hours after administration. In contrast with fast and potent effect of pyrrole, effect of monocrotaline was mild and delayed in development. These findings suggested that monocrotaline increased the porosity of not only endothelial but also alveolar membraneby active metabolite.
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Monocrotaline is a pyrrolizidine alkaloid contained in the seed of leguminous plant, crotalaria spectabilis. Regardless of the route of administration, it causes obliterative pulmonary vasculitis and pulmonary hypertension resulting in right sided heart failure by single dose in rats and many other domestic animals1'2). Even in human being, poisoning by pyrrolizidine alkaloids has been reported.
Because of their worldwide distribution and ease to access, these alkaloids are assumed to be one of the possible cause of dietary pulmonary hypertension^.
To clarify the action of monocrotaline may give some clue to understand the developmental mechanismof pulmonary hypertension in human being.
The toxicity of this alkaloid is supposed to be mediated by the metabolite, monocrotaline pyrrole, through the actions of microsomal enzymes in the liver. Although this active pyrrole, dehydromonocrotaline is extremely reactive, it is rapidly broken downto inactive metabolite in the presence of water and entirely eliminated from the body soon after administration40. Therefore, it seems likely that the earliest changes in the lung has the essential role in the development of sequential changes leading to the full brown pulmonary hypertension. Since the percentage unabsorbed decreased exponentially with time, the plotted data conformed to a straight line and the rate of absorption could be expressed in terms of a half time for absorption (Tl/2: the time for 50% of the dose to be absorbed).
Rates were also expressed in terms of an apparent firstorder rate constant(k), which was calculated by dividing 0.693 by the half-time in hours.
Absorption of 14C-urea was compared in Fig. 4 than that of urea with the regression line of %unabsorb=114.3e-°-0209t (n=32, r=-0.95) with Tl/2 of 53.2 minutes and k of 0.78/hr in control saline treated group. As illustrated in Fig. 6, 24 These findings confirmed the view that the pressor effect of the alkaloid on pulmonary circulation was not acted directly but exerted long after the elimination of monocrotaline from the body8j20).
To quantitate lung fluid and detect pulmonary edema, direct and invasive methodwas chosen amongvarious methods for its advantages13). Only 5mg/kg å of monocrotaline pyrrole was enough toincrease 
